Xilio Therapeutics (XLO) Stock: Buy, Sell, or Hold?
XLO - Xilio Therapeutics, Inc. Common Stock
$9.13
0.12 (1.33%)
▲
5d:
+2.47%
30d:
+1.78%
90d:
+0.33%
HOLD
MODERATE Confidence
Analysis Updated: Oct 7, 2026 12:00 AM ET
Earnings: Nov 12, 2026
Get Alerted When XLO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: XLO shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: XLO shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: XLO is currently trading at $9.13, which is considered extended relative to its 30-day fair value range of $8.92 to $9.06. From a valuation perspective, the stock is trading at a discount (Forward PE: -4.0) compared to its historical average (23.0). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, XLO is in a uptrend. Immediate support is located at $8.78, while resistance sits at $9.57.
Market Sentiment: The stock scores a mixed 48/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $20.00 (+122.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, XLO is in a uptrend. Immediate support is located at $8.78, while resistance sits at $9.57.
Market Sentiment: The stock scores a mixed 48/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $20.00 (+122.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$8.92 -
$9.06
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
55.7%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (48/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 122.0% below Wall St target ($20.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- NEUTRAL: Bottoming setup forming (48/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$8.92 -
$9.06
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$8.78
Resistance Level
$9.57
Current Trend
Uptrend
Technical data as of
Oct 8, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.04
Wall Street Target
$20.00
(+122.0%)
Revenue Growth (YoY)
131.2%
Profit Margin
-34.1%
PE vs Historical
-4.0 vs 23.0
CHEAP
Share & Embed Analysis
Last updated: October 08, 2026 3:10 PM ET
Data refreshes hourly during market hours. Next update: 4:10 PM
Data refreshes hourly during market hours. Next update: 4:10 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XLO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 49 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 47 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
14 analysts |
$146 | 60 BUY |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
19 analysts |
$18 | 42 HOLD |
|
RLAY
Relay Therapeutics Inc |
STRONG BUY
13 analysts |
$28 | 58 HOLD |